1011 — China NT Pharma Income Statement
0.000.00%
Last trade - 00:00- HK$55.46m
- HK$427.02m
- CNY7.37m
Annual income statement for China NT Pharma, fiscal year end - December 31st, CNY millions except per share, conversion factor applied.
R2019 December 31st | 2020 December 31st | 2021 December 31st | R2022 December 31st | 2023 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | PRESS | PRESS |
| Standards: | HKAS | HKAS | HKAS | — | — |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 153 | 222 | 227 | 0 | 7.37 |
| Cost of Revenue | |||||
| Gross Profit | 90.3 | 135 | 145 | — | — |
| Selling / General / Administrative Expenses | |||||
| Unusual Expense / Income | |||||
| Other Operating Expenses | |||||
| Total Operating Expenses | 404 | 335 | 287 | 10.7 | 11.9 |
| Operating Profit | -251 | -114 | -60 | -10.7 | -4.55 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -355 | -200 | -149 | -50 | -33.4 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -355 | -191 | -151 | -50 | -33.5 |
| Minority Interest | |||||
| Net Income Before Extraordinary Items | |||||
| Extraordinary Items | |||||
| Net Income | -588 | -358 | -150 | -66.4 | -144 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -588 | -358 | -150 | -66.4 | -144 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -0.144 | -0.103 | -0.084 | -0.026 | -0.021 |